CD8A and neoplasm: The major challenge for this approach is to find an appropriate tumor-associated antigen (TAA) that is exclusively expressed on tumor cells to avoid autoimmune diseases, with strong binding affinity to αβ-TCR to initiate robust TAA-specific CD8+ T-cells responses and long-lived memory T cells [152].